These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 29283507)

  • 1. Evaluation of Bioequivalence Between 0.5-mg Dutasteride Capsules Manufactured by GlaxoSmithKline and an Existing Formulation: A Randomized Study in Healthy Japanese Male Volunteers.
    Ino H; Itoh H; Doi Y; Igarashi H; Numachi Y
    Clin Pharmacol Drug Dev; 2018 Mar; 7(3):341-346. PubMed ID: 29283507
    [No Abstract]   [Full Text] [Related]  

  • 2. Bioequivalence Studies of a Reformulated Dutasteride and Tamsulosin Hydrochloride Combination Capsule and a Commercially Available Formulation.
    Kurczewski R; Bowen C; Collins D; Zhu J; Serbest G; Manyak M
    Clin Pharmacol Drug Dev; 2017 Sep; 6(5):508-516. PubMed ID: 28127948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative Bioavailability of Fixed-Dose Combinations of Tamsulosin and Dutasteride: Results From 2 Randomized Trials in Healthy Male Volunteers.
    Burns O; Zhu J; Manyak MJ; Ravindranath R; Koosha F; Haque N; Chung S
    Clin Pharmacol Drug Dev; 2018 May; 7(4):422-434. PubMed ID: 28800206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Formulation on the Pharmacokinetics of Dutasteride: Results from Two Phase I Studies.
    Fossler M; Zhu J; Roehrborn C; McAleese P; Manyak M
    Clin Drug Investig; 2016 Sep; 36(9):763-767. PubMed ID: 27356530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic bioequivalence studies of a fixed-dose combination of tamsulosin and dutasteride in healthy volunteers.
    Fossler MJ; Collins DA; Thompson MM; Nino A; Bianco JJ; Chetty D
    Clin Drug Investig; 2014 May; 34(5):335-49. PubMed ID: 24615171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and Bioequivalence of Two Formulations of Valsartan 80 mg Capsules: A Randomized, Single Dose, 4-Period Crossover Study in Healthy Chinese Volunteers Under Fasting and Fed Conditions.
    Wu Q; Wang X; Chen Q; Zou Y; Xu X; Li T; Yu C; Zhu F; Zhang KE; Jia J; Liu Y
    Drug Des Devel Ther; 2020; 14():4221-4230. PubMed ID: 33116410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic Study of a Soft Gelatin Capsule and a Solid-Supersaturatable SMEDDS Tablet of Dutasteride in Beagle Dogs.
    Kim JS; Ha ES; Park H; Choi DH; Kim MS; Baek IH
    Eur J Drug Metab Pharmacokinet; 2020 Apr; 45(2):235-241. PubMed ID: 31782125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial.
    Bhasin S; Travison TG; Storer TW; Lakshman K; Kaushik M; Mazer NA; Ngyuen AH; Davda MN; Jara H; Aakil A; Anderson S; Knapp PE; Hanka S; Mohammed N; Daou P; Miciek R; Ulloor J; Zhang A; Brooks B; Orwoll K; Hede-Brierley L; Eder R; Elmi A; Bhasin G; Collins L; Singh R; Basaria S
    JAMA; 2012 Mar; 307(9):931-9. PubMed ID: 22396515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Withdrawing α1-Blocker from Combination Therapy with α1-Blocker and 5α-Reductase Inhibitor in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective and Comparative Trial Using Urodynamics.
    Matsukawa Y; Takai S; Funahashi Y; Majima T; Kato M; Yamamoto T; Gotoh M
    J Urol; 2017 Oct; 198(4):905-912. PubMed ID: 28499730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man.
    Hazlehurst JM; Oprescu AI; Nikolaou N; Di Guida R; Grinbergs AE; Davies NP; Flintham RB; Armstrong MJ; Taylor AE; Hughes BA; Yu J; Hodson L; Dunn WB; Tomlinson JW
    J Clin Endocrinol Metab; 2016 Jan; 101(1):103-13. PubMed ID: 26574953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.
    Page ST; Hirano L; Gilchriest J; Dighe M; Amory JK; Marck BT; Matsumoto AM
    J Urol; 2011 Jul; 186(1):191-7. PubMed ID: 21575967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do 5α-Reductase Inhibitors Raise Circulating Serum Testosterone Levels? A Comprehensive Review and Meta-Analysis to Explaining Paradoxical Results.
    Traish AM; Krakowsky Y; Doros G; Morgentaler A
    Sex Med Rev; 2019 Jan; 7(1):95-114. PubMed ID: 30098986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease.
    Litim N; Bourque M; Al Sweidi S; Morissette M; Di Paolo T
    Neuropharmacology; 2015 Oct; 97():86-94. PubMed ID: 26006269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited influence of dutasteride on individual prostate-specific antigen variability in men with clinical benign prostatic hyperplasia.
    Takeshita H; Kawakami S; Kagawa M; Yano A; Okada Y; Morozumi M
    Int J Urol; 2018 Jun; 25(6):633-634. PubMed ID: 29693288
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia: long-term results from the combination of dutasteride and tamsulosin study.
    Chung BH; Lee SH; Roehrborn CG; Siami PF; Major-Walker K; Wilson TH; Montorsi F;
    Int J Urol; 2012 Nov; 19(11):1031-5. PubMed ID: 22774774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concentration-dependent effects of dutasteride on prostate-specific membrane antigen (PSMA) expression and uptake of
    Kranzbühler B; Salemi S; Umbricht CA; Deberle LM; Müller C; Burger IA; Hermanns T; Sulser T; Eberli D
    Prostate; 2019 Sep; 79(12):1450-1456. PubMed ID: 31233227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What are the predicting factors for the therapeutic effects of dutasteride in male patients with lower urinary tract symptoms? Investigation using a urodynamic study.
    Matsukawa Y; Kato M; Funahashi Y; Majima T; Yamamoto T; Gotoh M
    Neurourol Urodyn; 2017 Sep; 36(7):1809-1815. PubMed ID: 28102554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5α-reductase type 1 modulates insulin sensitivity in men.
    Upreti R; Hughes KA; Livingstone DE; Gray CD; Minns FC; Macfarlane DP; Marshall I; Stewart LH; Walker BR; Andrew R
    J Clin Endocrinol Metab; 2014 Aug; 99(8):E1397-406. PubMed ID: 24823464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The corpus cavernosum after treatment with dutasteride or finasteride: A histomorphometric study in a benign prostatic hyperplasia rodent model.
    Da Silva MHA; Costa WS; B Sampaio FJ; De Souza DB
    Asian J Androl; 2018; 20(5):505-510. PubMed ID: 29893293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opposing Effects of Cyclooxygenase-2 (COX-2) on Estrogen Receptor β (ERβ) Response to 5α-Reductase Inhibition in Prostate Epithelial Cells.
    Liu TT; Grubisha MJ; Frahm KA; Wendell SG; Liu J; Ricke WA; Auchus RJ; DeFranco DB
    J Biol Chem; 2016 Jul; 291(28):14747-60. PubMed ID: 27226548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.